GHK-Cu, Copper Binding, and Extracellular Matrix Remodelling: What the Published Studies Report

GHK-Cu is the copper-bound form of the tripeptide glycyl-histidyl-lysine, and the published literature retrieved here examines it principally as a copper-carrying species studied alongside extracellular matrix (ECM) remodelling endpoints in cell culture and animal models. Neither of the studies summarised below was conducted in human participants. One line of work framed GHK-Cu as a stable copper source within a composite delivery system (LNP-ATOX1/GHK-Cu@PCL-GelMA) designed to route copper to the Golgi apparatus, where copper-dependent enzymes such as lysyl oxidase (LOX) are reported to acquire copper for enzymatic activation [1]. In that system, GHK-Cu was described as providing sustained release of copper ions for cellular uptake, while lipid nanoparticles delivered mRNA encoding the copper chaperone ATOX1 [1]. The authors reported that in vitro the material system increased copper accumulation within the Golgi apparatus and raised measured LOX activity to 1.78 times that of the control group, alongside increased angiogenic capacity in cell-based assays [1]. The same report described ATOX1 upregulation as facilitating copper transport into the Golgi via ATP7A/B and as promoting copper-dependent translocation of ATP7A and Rac1 to the plasma membrane [1]. In a rabbit fascia defect model — an animal model, not a human study — the investigators reported greater collagen alignment and neovascularisation and described the outcome in terms of extracellular matrix reconstruction during fascia regeneration [1]. A separate and earlier study approached the peptide from the matrikine literature, in which small peptide fragments derived from extracellular matrix proteins are studied for tissue-repair activity, and noted that sustained delivery of such peptides at the site of interest is a practical constraint [2]. That work incorporated biotinylated GHK (Bio-GHK) into a collagen membrane and evaluated it in a rat dermal wound model [2]. Binding experiments in that report indicated that Bio-GHK associated with the collagen matrix and with red blood cell membranes more effectively than t-butyloxycarbonyl-substituted GHK (Boc-GHK) [2]. In the rat model, the peptide-incorporated collagen group was reported to show wound contraction, increased cell proliferation, and higher expression of antioxidant enzymes relative to collagen film alone and to untreated controls [2]. The authors also measured a roughly ninefold increase in copper concentration at the wound site with Bio-GHK-incorporated collagen, and interpreted their findings as linking the observed activity to both copper localisation and matrikine activity [2]. Taken together, the retrieved evidence base is preclinical. Both reports position GHK-Cu or GHK derivatives as vehicles that concentrate or deliver copper in a local matrix environment, with ECM-related readouts — LOX activity and collagen alignment in one case [1], collagen-matrix binding and tissue copper content in the other [2] — measured in cells and in animals. No human data on these endpoints appear in the studies cited here [1][2]. Researchers designing follow-up work should note the differing model systems (rabbit fascia defect [1] versus rat dermal wound [2]) and the differing peptide forms (copper-complexed GHK [1] versus biotinylated and Boc-substituted GHK [2]) when comparing outcomes across the two reports.